Douglas J. Biedenbach

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Determination of CEM-101 Activity Tested against Clinical Isolates of Neisseria meningitidis from a Worldwide Collection

Antimicrobial Agents and Chemotherapy (2010)

Douglas J. Biedenbach Mariana Castanheira Ronald N. Jones

The activity of CEM-101, a fluoroketolide, was compared to those of 11 other antimicrobial agents using the reference broth microdilution method tested against 103 Neisseria meningitidis strains, including ciprofloxacin-nonsusceptible isolates with confirmed gyrA (T91I) mutations. Among the tested isolates, 79.6% were serogroup B or C and all isolates were susceptible to ceftriaxone, azithromycin, minocycline, and rifampin. However, penicillin-nonsusceptible strains were observed (15.5%) and susceptibility to trimethoprim-sulfamethoxazole was only 50.5%. CEM-101 was the most active macrolide-like compound (MIC(90), < or = 0.015 microg/ml) compared with MIC(90)s of telithromycin (MIC(90), 0.03 microg/ml), azithromycin and clarithromycin (MIC(90), 0.12 microg/ml), and erythromycin (MIC(90), 0.25 microg/ml). CEM-101 could provide a potent alternative for the prophylaxis of meningococcal disease.

Broth microdilution

Sulfamethoxazole

Trimethoprim

Telithromycin

Neisseria

10.1128/aac.01812-09

Cite

Citations (10)

Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin American medical centers

Diagnostic Microbiology and Infectious Disease (2002)

Hélio S. Sader Ronald N. Jones Soraya Andrade-Baiocchi Douglas J. Biedenbach

Broth microdilution

Tazobactam

Amikacin

10.1016/s0732-8893(02)00469-8

Cite

Citations (100)

Evolution and dissemination of extended-spectrum β-lactamase-producing Klebsiella pneumoniae: Epidemiology and molecular report from the SENTRY Antimicrobial Surveillance Program (1997–2003)

Diagnostic Microbiology and Infectious Disease (2005)

Joseph R. DiPersio Lalitagauri M. Deshpande Douglas J. Biedenbach Mark A. Toleman Timothy R. Walsh

Aztreonam

Trimethoprim

Broth microdilution

Molecular Epidemiology

10.1016/j.diagmicrobio.2004.08.001

Cite

Citations (43)

Epidemiology and antimicrobial susceptibility of Gram-negative aerobic bacteria causing intra-abdominal infections during 2010–2011

Journal of Chemotherapy (2014)

Stephen Hawser Daryl J. Hoban Robert E. Badal Samuel K. Bouchillon Douglas J. Biedenbach

The study for monitoring antimicrobial resistance trends (SMART) surveillance program monitors the epidemiology and trends in antibiotic resistance of intra-abdominal pathogens to currently used therapies. The current report describes such trends during 2010–2011. A total of 25 746 Gram-negative clinical isolates from intra-abdominal infections were collected and classified as hospital-associated (HA) if the hospital length of stay (LOS) at the time of specimen collection was ≧48 hours, community-associated (CA) if LOS at the time of specimen collection was <48 hours, or unknown (no designation given by participating centre).A total of 92 different species were collected of which the most common was Escherichia coli: 39% of all isolates in North America to 55% in Africa. Klebsiella pneumoniae was the second most common pathogen: 11% of all isolates from Europe to 19% of all isolates from Asia. Isolates were from multiple intra-abdominal sources of which 32% were peritoneal fluid, 20% were intra-abdominal abscesses, and 16·5% were gall bladder infections. Isolates were further classified as HA (55% of all isolates), CA (39% of all isolates), or unknown (6% of all isolates). The most active antibiotics tested were imipenem, ertapenem, amikacin, and piperacillin–tazobactam. Resistance rates to all other antibiotics tested were high.Considering the current data set and high-level resistance of intra-abdominal pathogens to various antibiotics, further monitoring of the epidemiology of intra-abdominal infections and their susceptibility to antibiotics through SMART is warranted.

Ertapenem

Amikacin

Tazobactam

10.1179/1973947814y.0000000164

Cite

Citations (31)

Interpretive accuracy of the disk diffusion method for testing newer orally administered cephalosporins against Morganella morganii

Journal of Clinical Microbiology (1993)

Douglas J. Biedenbach Ronald N. Jones M E Erwin

Eight newer orally administered cephems (cefdinir, cefetamet, cefixime, cefpodoxime, cefprozil, ceftibuten, cefuroxime, and loracarbef) were tested against 100 clinical strains of Morganella morganii to determine the extent of serious interpretive very major (false-susceptible) errors when current criteria for the disk diffusion test are applied. Agar dilution MICs and disk diffusion tests were performed as recommended by the National Committee for Clinical Laboratory Standards (Villanova, Pa.) (NCCLS), and the methods were compared by regression analysis using the method of least squares and by error rate bounding. The following results are listed in the order of increasing error rates: cefdinir, loracarbef, and cefprozil, < or = 1% very major error; ceftibuten, 8% minor errors; cefuroxime, 21% minor errors; cefixime, cefpodoxime, and cefetamet, very major errors of 15, 24, and 36%, respectively. M. morganii produces unacceptable rates of test error with cefuroxime, cefixime, cefpodoxime, and cefetamet. The latter two cephalosporins currently have NCCLS table footnote warnings covering the problem observed with this organism. The inclusion of cefuroxime and cefixime in the NCCLS table footnote is strongly recommended.

Cefixime

Cefpodoxime

Cefdinir

Cefuroxime

Ceftizoxime

Morganella morganii

10.1128/jcm.31.10.2828-2830.1993

Cite

Citations (18)

Tigecycline Susceptibility Trends Among Pathogens Isolated From Complicated Skin and Soft-Tissue Infections in North and Latin America: 2011–2015

Open Forum Infectious Diseases (2016)

Douglas J. Biedenbach Martha Renteria Heidi Leister‐Tebbe Dan Sahm